In December, the U.S. Food and Drug Administration (FDA) approved nivolumab and hyaluronidase-nvhv (Opdivo Qvantig) for subcutaneous injection across all of nivolumab’s approved adult solid tumor indications, including melanoma.
Health Professionals
Report Highlights Role of Cancer-Associated Fibroblasts in Melanoma Metastases
The study could open the door to potential novel therapeutic targets.
New immunotherapy strategy targets macrophage receptors to enhance melanoma treatment
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called macrophage receptor with collagenous structure, or MARCO. Their study, published in the Journal for ImmunoTherapy of Cancer, shows that blocking MARCO in combination with a type of immunotherapy known as anti-CTLA4 therapy, significantly enhances tumor regression in melanoma, the deadliest form of skin cancer.
Tilsotolimod Provides No Added Benefit in Advanced Melanoma
The combination of tilsotolimod and ipilimumab does not improve response rates or survival outcomes over ipilimumab alone in patients with advanced melanoma, according to phase 3 trial results published in the Journal of Clinical Oncology.